TrialThe Lancet. Global health2024

Safety and immunogenicity of the Euvichol-S oral cholera vaccine for prevention of Vibrio cholerae O1 infection in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial.

Katerina Rok Song et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.